Press Release Hub logo
  • Submit a Release
  • Home
  • All
  • ESG
  • Health
  • Technology
  • Finance
  • Contributors

Additional data on BerGenBio's selective AXL inhibitor bemcentinib to be presented at the 2023 ESMO meeting

Contributed by: PR Newswire

Tags

BerGenBio

More Like This

New Data on BerGenBio's Selective AXL Inhibitor Bemcentinib Released Today at 2023 ESMO Meeting

BerGenBio Announces Poster Presentation at Upcoming SITC Meeting

BerGenBio Reports Third Quarter 2023 Financial Results

BerGenBio Announces Data from Biomarker Analyses in 2L NSCLC

BerGenBio First Quarter Results 2024: Advancing to the Next Stage of Development

BerGenBio Third Quarter Results 2024

BerGenBio Announces Safety Data from Dose Escalation Phase 1b in First Line NSCLC Patients

BerGenBio Second Quarter Results 2024: Solid clinical and financial progress

Pages

  • Home
  • All
  • ESG
  • Health
  • Technology
  • Finance
  • Contributors

Press Release Hub

  • Our Services
  • Submit a Release

Websites

  • PA Media Group
  • PA Mediapoint
  • Distribution Packages

© PA Media Group. 2025

Terms of Use

Privacy Policy

Contact Us